GITNUX MARKETDATA
Browse Our Category
Medical Conditions Disorders
Latest update:
Back Pain Statistics
Back pain is the leading cause of lost work time, and the latest figures for 2025 make it clear why clinics are seeing the same pattern again and again. What’s most unsettling is how often “routine” daily strain ends up costing more than people expect, so the statistics are worth reading before you assume it will pass.
Prostate Cancer Breast Cancer Statistics
Men and women face similar distant stage survival realities with 5-year relative survival of 30% for prostate cancer and 31% for breast cancer using SEER 2013–2019, yet screening guidance and trial results split sharply with PSA screening showing different outcomes across ERSPC and PLCO and tamoxifen plus targeted HER2 and abiraterone strategies reshaping recurrence and survival. The page also updates care context with U.S. breast cancer incidence at 133.1 per 100,000 women and tracks BRCA1 risk up to about 16% lifetime while global deaths remain high at 201,000 from prostate cancer and 177,000 from breast cancer in 2019.
Herpes 1 Statistics
CDC guidance now favors NAAT for genital herpes because it is more sensitive than culture, while the same trial shows valacyclovir lowered median HSV-2 genital transmission acquisition to 1.2 per 100 person years versus 2.2 with placebo. You will also see how HSV-1 spreads through partner turnover and symptom free saliva shedding, how faster healing outcomes stack up against long term recurrence and billions in modeled costs, plus the latest shift toward multiplex NAAT testing and telehealth follow up.
Chlamydia Statistics
If you are being treated for chlamydia, reinfection is not rare with CDC estimating 10% to 20% within 12 months, yet the right combination of partner treatment and antibiotic choice can make a measurable difference. From 2020 onward screening practices, test accuracy, and real world implementation to cure and persistent infection gaps where doxycycline performs better than azithromycin, plus the economic and QALY impact of expanding screening, this page pins down what the latest evidence suggests you can change and what it means for outcomes.
Organ Transplant Rejection Statistics
With rejection rates still changing patient by patient, the latest 2025 figures reveal how often the immune system pushes back despite modern transplant care and what that means for real long term outcomes. If you want the hard contrast between early red flags and later stability, this page lays out the organ transplant rejection statistics that clinicians use to keep risk from being a surprise.
Congestive Heart Failure Statistics
Congestive heart failure is still a major driver of hospital care, with 2026 projections and recent trends showing how quickly the burden can surge even as treatments advance. Get the numbers that connect survival, readmissions, and risk by age so you can see where progress is actually landing and where it is not.
Asbestos Deaths Statistics
Asbestos Deaths tracks the latest 2026 figures alongside the older patterns that still shape risk, showing how exposures from decades ago keep producing preventable fatalities today. The page makes the contrast plain, where one year’s count is rising or shifting even as prevention and reporting should be tightening.
Diabetic Amputation Statistics
Diabetic amputation data doesn’t just reflect how severe complications can get, it shows how quickly the risk accumulates and why prevention and early treatment still make the biggest difference. With the most recent figures currently available, this page highlights where diabetic foot outcomes are trending and what that shift means for avoiding the life changing escalation from ulcers to amputation.
Cholera Statistics
Cholera still moves quickly, with 2026 data highlighting how outbreaks can surge faster than health systems can respond. See the sharp contrast between reported cases and the conditions that drive them, so you understand what changes the curve and what does not.
Rheumatoid Arthritis Statistics
Rheumatoid arthritis affects about 0.5% to 1% of adults, yet it can quickly reshape life with flares, with roughly 1 in 3 people experiencing at least one flare each year and 60% reporting work disability at some point. See why early treatment matters as well as what it can change, from a 0.3% to 0.5% annual incidence rate and around 50% reaching low disease activity or remission within a year of treat to target to real world biologic retention of about 70% at 12 months.
Leukemia Survival Rate Statistics
Leukemia Survival Rate tracks the latest survival outcomes, including a 2026 snapshot that shows how treatment advances are shifting the odds. See where rates rise most by leukemia type and age, and why the differences matter more than a single average figure.
Kids Cancer Statistics
More than 1 in 5 children with cancer in the UK survive for at least 5 years, and that gap is the kind that keeps clinicians pushing for earlier diagnosis and better treatments. Read Kids Cancer’s latest statistics to see how survival, diagnosis, and outcomes don’t move at the same pace for every family.
Progeria Statistics
With an estimated 1 in 4 million live births worldwide, progeria remains vanishingly rare yet disproportionately revealing, and the latest counts in major registries can change how often clinicians see it and how quickly support reaches families. The page maps who is affected and where they are found, turning the surprise of extreme rarity into practical, up to date statistics you can actually use.
Fibroid Statistics
Fibroids affect women in ways that are bigger than many people expect and the latest reporting shows the gap is widening in 2026, not shrinking. If you want to understand what this means for symptoms, diagnosis, and treatment timing, these statistics put the most important patterns side by side so you can see where delays and outcomes truly diverge.
Bacterial Vaginosis Statistics
Bacterial vaginosis affects about 29% of women of reproductive age worldwide and most cases never announce themselves with symptoms, yet recurrence after standard treatment is common with up to half of women seeing BV come back within 3 to 6 months. These same microbiologic shifts are linked across studies to major outcomes including higher odds of HIV acquisition, preterm birth, postpartum endometritis, and postoperative infections, making the page essential for connecting day to day risk with the measurable public health burden.
Aortic Aneurysm Statistics
Aortic aneurysms can be quiet until they suddenly are not, and the latest statistics put the spotlight on how often this threat is missed. Get the most up to date numbers on who is most at risk, when size and symptoms turn dangerous, and what that means for prevention and early action.
Genital Wart Statistics
Genital warts statistics in 2025 reveal a clear gap between how common HPV-driven genital warts are and how late many people seek care, turning a manageable condition into a longer, more complicated experience. Read to understand what the newest trend data suggests for prevention and treatment timing, so you can act before symptoms linger or spread.
Pcos Pregnancy Statistics
PCOS affects about 1 in 10 people, and while roughly 70% experience reproductive or menstrual irregularities, PCOS pregnancy also comes with measurable odds shifts such as miscarriage risk up with a pooled OR around 1.3 and postpartum weight retention with 1.3 times higher odds. This page pulls together the latest treatment and prevention signals, from letrozole beating clomiphene citrate for conception at 41.0% vs 28.3% to metformin and metformin plus lifestyle impacts on outcomes like large for gestational age and gestational diabetes risk.
Breast Cancer In Women Statistics
Breast Cancer In Women brings together the most up to date screening, risk, treatment, and cost statistics, from a 20 percent share of DCIS found by screening in US SEER data to projected growth like the therapeutics market reaching 56.2 billion dollars by 2030. See how age shapes diagnosis and outcomes, why false alarms still affect mammography, and what financial strain looks like in real life alongside major advances such as adjuvant trastuzumab.
Pancreatic Cancer Survival Statistics
Pancreatic Cancer Survival statistics reveal a rare bright spot in 2026, where outcomes improve enough to change what “survival” can mean for real people. You will see exactly how survival rates shift by stage and treatment, and why the gap between early detection and late diagnosis is wider than most families expect.